

**MATERIAL CHANGE  
REPORT FORM 51-102F3**

1. **Reporting Issuer**

Canntab Therapeutics Limited (the “**Issuer**” or “**Canntab**”)  
223 Riviera Drive  
Markham, Ontario, L3R 5J6

2. **Date of Material Change**

March 3, 2021

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated on March 3, 2021 through Newsfile and filed on the system for electronic document analysis and retrieval (SEDAR) at [www.sedar.com](http://www.sedar.com).

4. **Summary of Material Change**

The Issuer has announced that it has fulfilled 80% of the purchase agreement entered into with MediPharm Labs Corp. in June 2020, through the completion of their second delivery of additional SKU's ordered.

5. **Full Description of Material Change**

The material change is fully described in the news release attached hereto as Schedule "A".

6. **Reliance on Section 7.1(2) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

For additional information with respect to this material change, the following person may be contacted:

Canntab Therapeutics Limited  
Jeffrey Renwick, CEO  
Tel: +1 289.301.3812  
Email: [jeff@canntab.ca](mailto:jeff@canntab.ca)

9. **Date of Report**

This report is dated as of the 12<sup>th</sup> day of March, 2021.

## Schedule "A"

### CANNTAB FULFILLS 80% OF ITS CONTRACT WITH MEDIPHARM LABS CORP.

TORONTO, March 3, 2021 /CNW/ - Canntab Therapeutics Limited ([CSE:PILL.CN](#)) ([OTCQB:CTABF](#)) ([FRA:TBFLF](#)) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2<sup>nd</sup> (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") ([TSE:LABS.TO](#)) ([OTC:MEDIF](#)) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately \$550,000.00. Canntab has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the Company and MediPharm Labs in June, 2020.

Further to Canntab's [previous announcement on December 1, 2020](#), the total purchase order was approximately \$1.3 Million. The 1<sup>st</sup> (first) delivery included 2.5mg THC and 5mg THC tablets. The final shipment which is currently in production and anticipated to be completed by month end is for a combination caplet which contains 25mg CBD and 5mg THC.

"We are very pleased having shipped 2 more SKU's to Medipharm Labs. Not only will this shipment reflect our second consecutive quarter of revenue, but more importantly, it also reflects our ability to ramp up our production by now having successfully produced and delivered 4 unique SKU's including 2.5mg THC, 5mg THC, 12.5mg CBD and 25mg CBD hard oral dose tablets and caplets. We are also excited about Medipharm's distribution capabilities to provincial wholesalers across Canada as well as National retailers. With our production capabilities now ramping, our focus will now be on expanding our sales channels by marketing directly to consumers and the health care community within Canada, states Larry Latowsky, Chief Executive Officer, Canntab Therapeutics Inc.

### Worldwide Expansion

Canntab is currently evaluating a number of partnering opportunities in Canada, the United States and Europe. Canntab will provide details of these efforts to its shareholders as soon as they become material. Canntab's unique patent technology and know how is easily exportable to a number of important worldwide markets where the opportunities for commercial expansion are both significant and immediate.

### Intellectual Property

Canntab has filed more than a dozen patent applications in the [United States](#) and [Canada](#) and other jurisdictions for which two have now been granted or allowed. Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/ sustained-release pharmaceutical grade delivery systems. Canntab has also applied for similar patents in Australia and Europe.

Canntab also intends to prove greater bioavailability of its tablets through a three (3) way cross over blood level study at a third-party Clinical Research Organization ("CRO"). The study will compare, among other important data, capsules from any Canadian Licensed Producer to the Canntab instant release ("IR") and extended release ("XR) tablets. This study is currently in the final planning phase and Canntab will provide further details on the breadth of the study, timing and results as soon as this information becomes available.

### About Canntab Therapeutics

## Schedule “A”

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

### **For further information:**

Canntab Therapeutics Limited Larry Latowsky  
Chief Executive Officer  
+1 833 301-3812 [larry@canntab.ca](mailto:larry@canntab.ca)

Canntab Therapeutics Limited Richard Goldstein  
Chief Financial Officer  
+1 833 301-3812 [richard@canntab.ca](mailto:richard@canntab.ca)

Frank Candido  
Business Development and Investor Relations Canntab Therapeutics Limited  
514-969-5530  
[Frank@canntab.ca](mailto:Frank@canntab.ca)